Lv1
76 积分 2021-03-22 加入
A randomized, controlled, multicenter, phase 3 study of RP1 (vusolimogene oderparepvec) combined with nivolumab vs physician’s choice of therapy in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3)
13小时前
已关闭
Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC
14天前
已完结
Neutrophils become pro-angiogenic in tumours
27天前
已完结
Subtypes of tumor-associated neutrophils and their roles in cancer immunotherapy
27天前
已完结
Neutrophil diversity and plasticity in tumour progression and therapy
27天前
已完结
The heterogeneity of neutrophils in cancer and its implication for therapeutic targeting
29天前
已完结
Interferon-stimulated neutrophils as a predictor of immunotherapy response
1个月前
已完结
From complexity to consensus: A roadmap for neutrophil classification
1个月前
已完结
Neutrophil Regulation of Immunotherapy for Cancer is Controlled by Type Ii Interferon
1个月前
已完结
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy
1个月前
已完结
皖公网安备34019202002308
